

March 6, 2009

## Spermatech enters hit to lead program

**Oslo, Norway** – Spermatech has successfully completed its high-throughput screening (HTS) program with Evotec. The screen has identified several hit series against one of their sperm specific target proteins important for male fertility. Evotec's library of 250 000 drug-like compounds was screened in a cellular assay. The hit series will be investigated as part of a hit-to-lead medicinal chemistry program at Evotec.

**Eirik Næss-Ulseth, Chief Executive Officer at Spermatech says:** "We are pleased to announce that we have successfully completed our HTS program. The most promising compounds will now be transformed into lead series' after medicinal chemistry optimization. The successful screening, identification of hits and initiation of subsequent optimization represents an important milestone for our company."

### **About Spermatech**

Spermatech was established in 2002 by researchers at the University of Oslo. The company is a pioneer in the development of a reversible non-hormonal contraceptive for men. Spermatech's technologies are based on the discovery of proteins that are crucial for sperm motility. These proteins are only found in mature sperm cells and this exclusive location makes it possible to develop drugs without side effects. Spermatech is now performing a hit-to-lead program on the most promising hits from high-throughput screening.

### **For further information, please contact:**

Eirik Næss-Ulseth  
Chief Executive Officer (CEO)  
[eirik@spermatech.com](mailto:eirik@spermatech.com)  
Tel: +47 22 14 70 87

Spermatech AS  
Forskningsveien 2A  
0373 Oslo, Norway  
[www.spermatech.com](http://www.spermatech.com)